Table 1 Immune checkpoint inhibitors approved by the Food and Drug Administration in USA
Ipilimumab CTLA-4 | Nivolumab PD-1 | Pembrolizumab PD-1 | Atezolizumab PD-L1 | Avelumab PD-L1 | Durvalumab PD-L1 | |
|---|---|---|---|---|---|---|
Malignancy | ||||||
Melanoma | √*(3/2011) | √*(12/2014) | √*(9/2014) | |||
Non-small cell lung cancer | √ (3/2015) | √ (10/2015) | √ (10/2016) | |||
Renal cell carcinoma | √ (11/2015) | |||||
Hepatocellular carcinoma | √ (9/2017) | |||||
Classical Hodgkin’ s lymphoma | √ (5/2016) | √ (3/2017) | ||||
Head & neck squamous cell carcinoma4 | √ (11/2017) | √ (8/2016) | ||||
Urothelial Carcinoma | √ (2/2017) | √ (5/2017) | √*(5/2016) | √ (5/2017) | √*(5/2017) | |
Colorectal cancer with high msi/mrd | √ (8/2017) | |||||
Gastric cancer | √ (9/2017) | |||||
Solid tumor with high msi/mrd | √ (7/2017) | |||||
Merkel-cell carcinoma | √* (3/2017) | |||||
Bladder Cancer | √ (04/2017) | |||||